Pharmacist Substitution Rules Shape Canada's Generic Semaglutide Rollout

Canadian pharmacists in most provinces can substitute the Dr. Reddy's Laboratories generic semaglutide injection — authorized by Health Canada on April 28, 2026 as the first generic version of Ozempic approved in any G7 country — without requiring a new prescription, provided the original script does not specify "no substitution".

The April 28 authorization

Health Canada confirmed on April 28, 2026 that it had authorized a generic semaglutide injection filed by Dr. Reddy's Laboratories, referencing the brand-name product from Novo Nordisk. The regulator described the product as a complex synthetic version that is pharmaceutically equivalent to the brand reference and said it met Health Canada's criteria for safety, efficacy and quality for generic drugs.

Health Canada also stated that eight other generic semaglutide submissions remain under active review, with additional regulatory decisions expected in the coming weeks and months.

How substitution works at the pharmacy counter

According to patient guidance published after the authorization, in most Canadian provinces a pharmacist can substitute a generic version of a prescribed product without a new prescription, as long as the prescriber has not written "no substitution" or "dispense as written" on the original script. Some provinces and individual pharmacies prefer to confirm with the patient or prescriber before substituting.

Patients who want to switch deliberately rather than at the next refill can ask their prescriber to issue a new prescription specifying the generic, which removes ambiguity at the counter.

Pricing framework and insurance mechanics

Generic pricing in Canada follows a tiered framework set by the pan-Canadian Pharmaceutical Alliance, under which the first generic is priced at a percentage of the brand reference and prices step down further as additional manufacturers reach pharmacy shelves. Coverage decisions by private insurers and provincial drug plans typically lag the price drop by weeks to months.

Patients with private insurance will likely be switched automatically because mandatory substitution is standard across most plans, while cash-pay patients can expect immediate savings that deepen as more generics enter the market. Current pharmacy pricing listed on GLP1Prices.ca shows brand-name Ozempic ranging from roughly $86 to $663 CAD per package across Canadian pharmacies, giving a baseline against which generic pricing will be measured.

What differs between brand and generic

Patient guidance notes that the active ingredient is identical and that Health Canada's bioequivalence standard requires the generic's pharmacokinetic measures — AUC and Cmax — to fall within an accepted range of the reference product. Differences may exist in inactive ingredients (excipients) and in the injection device itself, including pen design, needle gauge and dose-dial mechanics.

The April 28 authorization covers the same specific authorized use as the branded reference product. Semaglutide is also marketed in Canada under a separate brand with a distinct Health Canada authorization and different labelling and clinical-data requirements, and the new generic authorization does not extend to that separate authorization.

Rollout and consumer-facing channels

Generic supply will shift over the coming months as Health Canada reviews additional submissions, with urban pharmacies likely to stock the product before rural locations as it moves through provincial wholesalers. Consumer-facing telehealth brand Hers has launched a Canadian waitlist page stating that generic semaglutide is "now here" in Canada and that the product is manufactured by Apotex, which the company describes as one of Canada's largest pharmaceutical companies.

The Hers page also states that when the first generics arrive, the cost of semaglutide medications is expected to drop significantly, with further reductions as more generics enter the market, and that brand-name prices are also likely to come down as competition increases.

• Readers tracking Health Canada decisions on remaining filings can follow our generic semaglutide tracker.
• Patients wondering whether their plan will cover the generic can use our insurance coverage checker.
• Common questions about brand products including Wegovy, Rybelsus, Mounjaro and Zepbound are answered in our FAQ.

This article is for informational purposes only and does not constitute medical advice.

Sources

• Canada becomes the first G7 country to approve a generic ...
• Generic Semaglutide in Canada: A Patient Guide
• Generic submissions under review
• Generic Semaglutide Coming to Canada 2026 | Get Notified